Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + paclitaxel + carboplatin
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Cediranib + paclitaxel + carboplatin** is an investigational combination therapy primarily studied in advanced solid tumors, including non-small cell lung cancer (NSCLC) and metastatic or recurrent cervical cancer. Cediranib is a potent oral small molecule inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), blocking angiogenesis required for tumor growth. Paclitaxel, a microtubule inhibitor, and carboplatin, a DNA-damaging platinum agent, are chemotherapeutic agents used to kill or inhibit the proliferation of cancer cells. This combination aims to synergistically inhibit tumor growth by simultaneously blocking tumor angiogenesis and directly killing tumor cells. Clinical trials have shown enhanced tumor responses and progression-free survival compared to chemotherapy alone, but tolerability issues have been noted at some dosing regimens[1][2][3][4][7]. The combination has mainly been investigated in randomized phase II and III studies for advanced NSCLC and recurrent/metastatic cervical cancer, but is not an approved standard of care.
- Other names
- cediranib maleate + paclitaxel + carboplatin
02
Targets
ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)DNAFGFR1 (Fibroblast growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)SRC (Proto-oncogene tyrosine-protein kinase Src)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cediranib + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + paclitaxel + carboplatin.